{"id":"NCT01350999","sponsor":"Takeda","briefTitle":"Long-term Efficacy and Safety Study of TAK-085 in Participants With Hypertriglyceridemia","officialTitle":"A Phase 3 Long-term Study of TAK-085 in Subjects With Hypertriglyceridemia","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2009-11","primaryCompletion":"2011-01","completion":"2011-01","firstPosted":"2011-05-10","resultsPosted":"2016-09-20","lastUpdate":"2016-09-20"},"enrollment":503,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Hypertriglyceridemia"],"interventions":[{"type":"DRUG","name":"omega-3-acid ethyl esters 90 (TAK-085)","otherNames":["LOVAZA","Omacor"]},{"type":"DRUG","name":"Eicosapentaenoic acid-ethyl (EPA)","otherNames":[]}],"arms":[{"label":"TAK-085 2 g","type":"EXPERIMENTAL"},{"label":"TAK-085 4 g","type":"EXPERIMENTAL"},{"label":"EPA-E 1.8 g","type":"ACTIVE_COMPARATOR"}],"summary":"The purpose of this study is to determine the safety and efficacy of TAK-085, once daily (QD) or twice daily (BID), compared to ethyl eicosapentaenoate (EPA-E), three times daily (TID) in participants with hypertriglyceridemia undergoing lifestyle modification.","primaryOutcome":{"measure":"Number of Participants With Treatment Emergent Adverse Events (TEAEs)","timeFrame":"52 Weeks","effectByArm":[{"arm":"TAK-085 2 g","deltaMin":106,"sd":null},{"arm":"TAK-085 4 g","deltaMin":110,"sd":null},{"arm":"EPA-E 1.8 g","deltaMin":109,"sd":null}],"pValues":[]},"eligibility":{"minAge":"20 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":0,"countries":[]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":5,"n":165},"commonTop":["Nasopharyngitis","Upper respiratory tract inflammation","Pharyngitis","Blood creatine phosphokinase increased","Back pain"]}}